The CheckMate-7FL study was designed very similarly to the KEYNOTE-756 study to evaluate the efficacy and safety of nabulizumab in combination with NACT and adjuvant endocrine therapy in patients with high-risk ER+/HER2- high-risk breast cancer. Here, ERBB2 is linked to breast carcinoma.